CNXC Stock Forecast & Price Target

Concentrix is supported by a durable cash-generation profile, with Q3 revenue of $2.45B slightly below guidance but non-GAAP operating income of $309M, a 12.6% margin, beating expectations and expanding 30 bps year over year. Its positive outlook is strengthened by rapid iX adoption, including 61 deployments, 30,000+ advisors live, and 63% sequential new-logo AI sales growth, which should offset near-term revenue dips from automation and client offshore shifts as deployments become accretive within a couple of quarters. Despite these headwinds, management reaffirmed $630M-$650M of full-year adjusted free cash flow, expects about $2B over the next three years, and continues to reduce net debt, leaving the stock attractively valued at under 4x EV/EBITDA with a self-funding deleveraging story.

Concentrix is facing a deteriorating fundamental backdrop as revenue guidance was cut for the second consecutive quarter, with Q3 revenue down 0.5% in constant currency and Q4 guided to decline 3%-5%, leaving full-year growth at a slight decline. The weakness appears structural rather than temporary, driven by faster AI adoption, offshoring headwinds near 3%, and the accelerated exit of two hyperscaler client relationships, while key verticals such as healthcare fell 14% and technology and consumer electronics declined 6%. Despite $2.462 billion of Q2 revenue and $2.63 EPS, adjusted EBITDA missed expectations at $347.4 million, margins compressed, net debt remained elevated at 3.0x, and $175 million of restructuring charges underscore ongoing pressure.